Alnylam (ALNY) PT Cut to $58 at Jefferies

October 6, 2016 6:47 AM EDT
Get Alerts ALNY Hot Sheet
Price: $38.16 -2.05%

Rating Summary:
    13 Buy, 7 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade ALNY Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Jefferies analyst Gena Wang lowered her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $58.00 (from $86.00) but maintained a Buy rating after the company announced termination of revusiran Ph3 due to mortality imbalance.

Wang commented, "Following recent discontinuation of ALN-AAT, ALNY announced termination of revusiran Ph3 due to mortality imbalance. While longer follow-up would be needed to rule out similar safety concerns for the overall technology platform, the setback might be program/disease specific as suggested by our analysis. However, we see high risk for the ‘TTRsc02 program given seemingly lack of efficacy with revusiran. We lower PT to $58."

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $70.30 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co, Gena Wang

Add Your Comment